GlassScriptPhysician profile
Virginia Elesho
NPI 1770545394
$3,218.19
in general payments reported to CMS, 2019-2025
35 companies · $671 in 2025
The $671 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $286 · 2023: $482 · 2024: $1,159 · 2025: $671.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,311.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $451.63 | 2021-2025 | |
| Lilly USA, LLC | $384.26 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $365.08 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $344.12 | 2021-2025 | |
| Amgen INC. | $219.70 | 2021-2025 | Otezla, Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $147.85 | 2022-2025 | |
| Exact Sciences Corporation | $144.81 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.59 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $100.95 | 2021-2025 | Breztri |
| Esperion Therapeutics, INC. | $90.81 | 2021 | |
| Janssen Biotech, INC. | $78.93 | 2024-2025 | Tremfya |
| Astellas Pharma US INC | $67.02 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $62.56 | 2021-2024 | Freestyle Libre 3 |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.20 | 2025 | Caplyta |
| Horizon Therapeutics Plc | $55.58 | 2021-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.14 | 2021-2024 | |
| Medicomp INC | $48.12 | 2023-2024 | Telepatch Cardiac Monitor |
| Vanda Pharmaceuticals INC. | $44.27 | 2022 | |
| Merck Sharp & Dohme LLC | $37.68 | 2021 | |
| Acadia Pharmaceuticals INC | $33.40 | 2024 | Nuplazid |
| Almatica Pharma LLC | $29.51 | 2021 | |
| Leo Pharma INC. | $28.70 | 2025 | Adbry |
| Mylan Specialty L.P. | $28.08 | 2023 | Yupelri |
| Irhythm Technologies, INC. | $25.88 | 2023 | Zio Xt Patch |
| Xeris Pharmaceuticals, INC. | $22.67 | 2025 | Gvoke Hypopen |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.54 | 2024 | Cabtreo, Jublia |
| Phathom Pharmaceuticals, INC. | $21.88 | 2024 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $19.05 | 2023 | Rexulti |
| Jazz Pharmaceuticals INC. | $16.31 | 2021 | |
| Sunovion Pharmaceuticals INC. | $15.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.49 | 2021 | |
| Amarin Pharma, INC. | $15.25 | 2021 | |
| Arcutis Biotherapeutics, INC. | $15.24 | 2025 | Zoryve |
| Kowa Pharmaceuticals America, INC. | $14.67 | 2025 | Zoryve |
| Medtronic, INC. | $13.47 | 2025 | Inceptiv |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Elesho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.